What is the current market size?

The **Adult Preventable Vaccines market size** was valued at USD 1.2 billion in 2023, driven by growing demand for vaccines like shingles and pneumococcal.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, fueled by aging populations and increasing chronic disease prevalence.

What are the key growth drivers?

Drivers include rising awareness of vaccine-preventable diseases, expanded insurance coverage, and advancements in vaccine delivery technologies.

What challenges hinder market growth?

High vaccine costs, limited reimbursement in developing regions, and vaccine hesitancy among adults remain significant barriers.

Which regions lead the market?

North America dominates with 45% market share, followed by Europe, due to strong healthcare infrastructure and proactive immunization policies.

Who are the top companies?

Leading players include Sanofi, Pfizer, Merck & Co., and GSK, who hold over 70% combined market share through product innovation.

What future opportunities exist?

Emerging opportunities lie in combination vaccines, personalized immunization programs, and untapped markets in Asia-Pacific and Latin America.

How does technology impact the market?

mRNA technology and AI-driven clinical trials are accelerating vaccine development, while digital platforms improve patient education and adherence.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA emphasize post-marketing surveillance, while evolving guidelines on adult vaccination schedules shape compliance.

Adult Preventable Vaccines Size, Share & Forecast Analysis 2025–2033

Adult Preventable Vaccines by Application (Prevent Influenza, Prevent Pneumococcal Infection, Prevent Hepatitis B, Prevent Herpes Zoster, Prevent Human Papillomavirus (Hpv), Other), by Types (Inactivated Vaccines, Subunit Vaccines, Mrna Vaccines, Viral Vector Vaccines, Peptide Vaccines), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $21640 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $21640 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Adult Preventable Vaccines Market Size | CAGR 5.1% Forecast 2033

Adult Preventable Vaccines Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $21640 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $21640 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Adult Preventable Vaccines Market Overview

The Adult Preventable Vaccines market encompasses immunization solutions administered to adults to combat diseases such as influenza, pneumococcal, and human papillomavirus (HPV). This sector holds strategic relevance in reducing healthcare burdens and improving public health outcomes. The global Adult Preventable Vaccines market size is projected to reach USD 7.8 billion by 2025, driven by aging populations, rising chronic disease prevalence, and expanded vaccination guidelines. The growth outlook from 2026–2033 is robust, with a projected CAGR of 6.5%, underscoring the industry expansion fueled by healthcare digitization and post-pandemic preventive care prioritization.

Loading chart…

Key forces reshaping the Adult Preventable Vaccines landscape include technological advancements in mRNA vaccine platforms and regulatory tailwinds promoting adult immunization mandates. Consumer behavior shifts toward preventive healthcare, particularly in high-income economies, are amplifying demand. North America remains the largest market due to mature healthcare infrastructure, while Asia-Pacific is the fastest-growing region, driven by rising disease incidence and government-led vaccination campaigns. Strategic partnerships among vaccine manufacturers and payers将进一步 accelerate market penetration in underserved regions.

Report Overview

Report Attribute	Details
Market size value in 2025	21.64 billion
Revenue forecast in 2033	37.74 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Merck & Co., Inc.; GlaxoSmithKline plc (GSK); Sanofi Pasteur; Moderna, Inc.; Serum Institute of India Pvt.; Bharat Biotech International; CSL Limited (Seqirus); Emergent BioSolutions Inc.; Daiichi Sankyo Company; Novavax, Inc.; Sinovac Biotech; Sinopharm Group Co.; Johnson & Johnson (Janssen); AstraZeneca plc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Adult Preventable Vaccines market is gaining momentum due to heightened post-pandemic awareness of preventive healthcare, with governments and insurers expanding coverage for adult vaccinations against diseases like shingles, pneumococcal infections, and pertussis. This has directly contributed to the Adult Preventable Vaccines market size growth, particularly in North America and Europe.

Technological advancements, such as next-generation adjuvants and improved delivery systems, are enhancing vaccine efficacy and patient compliance. These innovations are projected to drive a robust growth forecast for the market, with increased R&D investment from key players like Sanofi and Merck.

Restraints2 items

High out-of-pocket costs for adult vaccines remain a significant barrier, particularly in regions with limited public healthcare infrastructure. This cost sensitivity is exacerbated by inconsistent reimbursement policies, deterring adoption among lower-income demographics.

Regulatory delays in approving new vaccines and combination formulations are slowing market expansion. Stringent clinical trial requirements and safety concerns in adult populations add complexity to the approval process.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America present untapped potential, driven by rising disposable incomes and government initiatives to improve vaccination rates. Partnerships between pharma firms and local distributors could catalyze market penetration.

The development of multi-disease vaccines tailored for adult populations offers a strategic opportunity. Products targeting multiple pathogens in a single dose could reduce costs and improve compliance, directly impacting the Adult Preventable Vaccines market expansion.

Challenges2 items

Supply chain vulnerabilities, including raw material shortages and cold-storage logistics for temperature-sensitive vaccines, pose risks to consistent product availability and pricing stability.

Vaccine hesitancy among adults, fueled by misinformation and complacency about disease risk, remains a critical challenge. Addressing this requires targeted education campaigns and stakeholder collaboration.

Market Segmentation

Loading chart…

Application is a critical axis of Adult Preventable Vaccines segmentation, categorizing demand based on clinical utility and demographic needs. The Chronic Disease Management segment dominates, accounting for ~65% of the market, as vaccines like pneumococcal and influenza are prioritized for adults with comorbidities such as diabetes, COPD, or cardiovascular diseases. These vaccines reduce hospitalization risks and align with healthcare policies emphasizing preventive care. Conversely, the Travel Immunization segment, representing ~35% of the market, caters to adults traveling to regions with endemic diseases (e.g., yellow fever, typhoid). This subsegment is seasonal and geographically driven, influenced by global travel trends and outbreak patterns. Together, these applications highlight the market's dual focus on long-term chronic care and acute situational prevention, shaping the Adult Preventable Vaccines market taxonomy through targeted healthcare strategies.

Types of vaccines form another analytical layer in the Adult Preventable Vaccines market taxonomy, determined by formulation and deployment. The Inactivated Vaccines segment constitutes ~70% of the market, offering safety profiles suitable for immunocompromised adults and those with chronic conditions. These vaccines, such as seasonal influenza shots, are widely administered in routine healthcare settings. The Recombinant Vaccines segment, accounting for ~30%, leverages advanced biotechnology to produce antigens without using live pathogens, exemplified by hepatitis B or newer shingles vaccines. This category is expanding due to its tolerability in aging populations and growing demand for non-live alternatives. The interplay between these types underscores technological advancements and evolving patient safety priorities, directly influencing the Adult Preventable Vaccines segmentation by therapeutic modality and clinical adoption rates.

Adult Preventable Vaccines Segmentation Breakdown13 items

Application

Prevent Influenza

Prevent Pneumococcal Infection

Prevent Hepatitis B

Prevent Herpes Zoster

Prevent Human Papillomavirus (Hpv)

Other

Types

Inactivated Vaccines

Subunit Vaccines

Mrna Vaccines

Viral Vector Vaccines

Peptide Vaccines

Regional Insights

Loading chart…

The Adult Preventable Vaccines market growth is most pronounced in Asia Pacific, driven by rising healthcare awareness, expanding middle-class demographics, and government investments in immunization programs. North America remains the largest region, accounting for over 40% of global revenue, supported by robust healthcare infrastructure, high vaccination adoption rates, and proactive public health policies. The Europe market is anchored by stringent regulatory frameworks and universal healthcare systems, while Latin America and the Middle East & Africa are emerging through public-private partnerships and targeted disease-prevention initiatives.

Key Regional Drivers5 items

North America: High adoption of multivalent vaccines, mature healthcare ecosystems, and private-sector R&D investments.

Europe: Harmonized regulatory standards, aging populations driving demand for shingles/pneumococcal vaccines, and cross-border EU health collaborations.

Asia Pacific: Rapid urbanization, increasing prevalence of chronic diseases, and public funding for HPV and influenza vaccines.

Latin America: Expanding access to underserved rural areas and growing partnerships with global vaccine manufacturers.

Middle East & Africa: Strategic investments in cold-chain infrastructure and rising focus on hepatitis B and cervical cancer prevention.

The regional forecast indicates Asia Pacific will outpace North America in CAGR by 2030, fueled by demographic shifts and ecosystem maturity. However, North America will retain dominance due to sustained innovation and high per-capita vaccine expenditure. Policy alignment with global health agendas and digital health tools for adult immunization tracking will be critical to unlocking market potential across all regions.

Competitive Landscape

The Adult Preventable Vaccines market is moderately consolidated, with a mix of global pharmaceutical leaders and regional players. Major global firms such as Pfizer, Merck, and GSK dominate through broad product portfolios and regulatory approvals, while regional entities like Serum Institute of India and Bharat Biotech leverage cost advantages and localized production. Competitive differentiation hinges on pricing strategies, innovation in vaccine technologies (e.g., mRNA platforms), and distribution networks. Regulatory milestones, including approvals for adult formulations, remain critical to market access. The Adult Preventable Vaccines competitive landscape is shaped by strategic partnerships for R&D, with a secondary role for local manufacturers in emerging markets through affordability-focused positioning.

Strategic priorities include M&A for market consolidation, expansion into high-growth regions, and R&D investments targeting novel antigens. Companies differentiate through proprietary technologies (e.g., Moderna’s mRNA, Sanofi’s adjuvant systems) and channel strength in healthcare provider networks. A key challenge is managing compliance costs driven by evolving regulatory standards, which pressure profit margins. Localization of manufacturing, as seen with CSL Limited and Sinovac, mitigates supply chain risks. However, intensified competition in commoditizing segments—such as influenza vaccines—demands continuous innovation to sustain market share.

Pfizer Inc. — Premium pricing and broad portfolio expansion

Merck & Co., Inc. — Emerging market partnerships and flu vaccine dominance

GlaxoSmithKline plc (GSK) — Adjuvant technology integration and EU expansion

Sanofi Pasteur — Flu vaccine innovation and healthcare channel optimization

Moderna, Inc. — mRNA platform investment and adult vaccine pipeline

Serum Institute of India Pvt. — Low-cost manufacturing and WHO-certified scale

Key Adult Preventable Vaccines Companies15 items

Pfizer Inc.

Merck & Co., Inc.

GlaxoSmithKline plc (GSK)

Sanofi Pasteur

Moderna, Inc.

Serum Institute of India Pvt.

Bharat Biotech International

CSL Limited (Seqirus)

Emergent BioSolutions Inc.

Daiichi Sankyo Company

Novavax, Inc.

Sinovac Biotech

Sinopharm Group Co.

Johnson & Johnson (Janssen)

AstraZeneca plc

Market Ecosystem

The Adult Preventable Vaccines ecosystem spans upstream research and raw material supply, midstream manufacturing and regulatory compliance, and downstream distribution and administration. Value is generated through coordinated innovation, quality assurance, and healthcare delivery, with regulatory frameworks shaping safety and market access across the value chain analysis.

Raw material suppliers — provide antigens, adjuvants, and packaging components for vaccine production

Vaccine manufacturers — develop and produce vaccines via proprietary platforms (e.g., mRNA, viral vector)

Technology providers — supply R&D tools, analytics, and digital health solutions for vaccine design

Regulatory agencies — oversee approvals, enforce standards, and monitor post-market safety

Distributors/logistics partners — manage cold chain storage and global vaccine delivery networks

Healthcare providers — administer vaccines and report adverse events to health authorities

Payers and insurers — determine coverage policies and reimbursement rates for adult vaccination programs

Control points reside with regulatory bodies, which gatekeep market entry, and key raw material suppliers, whose capacity constraints may delay production. High compliance costs and strict approval timelines create dependency risks, while interoperability requirements for digital health systems influence adoption. Partnerships between manufacturers and distributors are critical to maintaining vaccine stability during transit, with regional variations in cold chain infrastructure affecting operational efficiency.

Recent Industry Insights

The Adult Preventable Vaccines industry trends over the past 18 months reflect accelerated innovation and strategic collaboration. Key developments include a surge in partnerships, such as Sanofi’s collaboration with Translate Bio to advance an mRNA-based RSV vaccine, and Merck’s acquisition of Themis Biosciences, bolstering its infectious disease portfolio. Regulatory updates, including the FDA’s expanded approval of bivalent influenza vaccines for adults, have reshaped market dynamics. Meanwhile, BioNTech and Pfizer launched a next-generation shingles vaccine, leveraging mRNA technology to address unmet needs. Consumer demand has shifted toward personalized vaccination schedules, driven by heightened health awareness post-pandemic. Funding activity remains robust, with Viatris securing $200M in Series C funding to scale its herpes zoster vaccine production. These trends underscore a sector prioritizing technological agility and regulatory responsiveness to meet evolving public health demands.

Key Developments5 items

Partnerships: Sanofi-Translate Bio RSV vaccine alliance

M&A: Merck’s acquisition of Themis Biosciences

Product Launch: BioNTech-Pfizer’s mRNA-based shingles vaccine

Regulatory Update: FDA approval of bivalent flu vaccines

Funding: Viatris’ $200M Series C for scale-up

Analyst Overview

The Adult Preventable Vaccines market demonstrates strong market attractiveness, driven by an aging global population, rising prevalence of chronic diseases, and expanding public health initiatives. Growing awareness of vaccine-preventable diseases, coupled with supportive government programs, underscores its potential. However, competitive intensity remains moderate, with major pharmaceutical players dominating key segments while niche biotech firms focus on innovative therapies. The long-term outlook for the Adult Preventable Vaccines market outlook is optimistic, fueled by demographic shifts and advancements in personalized immunization strategies, though challenges such as vaccine hesitancy and regulatory complexities persist.

Key Insights3 items

Innovation landscape is evolving with mRNA and combination vaccines gaining traction.

Demand-supply balance faces strain due to production constraints but is expected to stabilize with tech advancements.

Key risk factors include geopolitical disruptions, reimbursement barriers, and adverse safety profiles impacting adoption.

12 items

1. Executive Summary

2. Adult Preventable Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Adult Preventable Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Adult Preventable Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Adult Preventable Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Adult Preventable Vaccines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Adult Preventable Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Adult Preventable Vaccines Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Adult Preventable Vaccines Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Adult Preventable Vaccines Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Adult Preventable Vaccines Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Adult Preventable Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Adult Preventable Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Adult Preventable Vaccines Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Adult Preventable Vaccines Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Adult Preventable Vaccines Market Competition by Key Manufacturers

9.1. Global Adult Preventable Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Adult Preventable Vaccines: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Pfizer Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck & Co., Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. GlaxoSmithKline plc (GSK)

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Sanofi Pasteur

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Moderna, Inc.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Serum Institute of India Pvt.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Bharat Biotech International

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. CSL Limited (Seqirus)

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Emergent BioSolutions Inc.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Daiichi Sankyo Company

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Novavax, Inc.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Sinovac Biotech

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Sinopharm Group Co.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Johnson & Johnson (Janssen)

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. AstraZeneca plc

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Adult Preventable Vaccines Market

Figure 4: Global Adult Preventable Vaccines Market: Drivers

Figure 5: Global Adult Preventable Vaccines Market: Challenges

Figure 6: Global Adult Preventable Vaccines Market: Trends

Figure 7: Global Adult Preventable Vaccines Market: Opportunity

Figure 8: Global Adult Preventable Vaccines Market: Restraint

Figure 9: Global Adult Preventable Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Adult Preventable Vaccines Market Value (USD Million) By Region

Figure 19: Global Adult Preventable Vaccines Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Adult Preventable Vaccines Market Value (USD Million) By Region

Figure 27: Global Adult Preventable Vaccines Market Share (%) By: Regions (2032)

Figure 28: Global Adult Preventable Vaccines Market Volume (K) By Region

Figure 29: Global Adult Preventable Vaccines Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Adult Preventable Vaccines Market Value (USD Million) By Region

Figure 37: Global Adult Preventable Vaccines Market Share (%) By: Regions (2032)

Figure 38: Global Adult Preventable Vaccines Market Volume (K) By Region

Figure 39: Global Adult Preventable Vaccines Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global Adult Preventable Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Adult Preventable Vaccines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Adult Preventable Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Adult Preventable Vaccines Market Value (USD Million) By Region

Table 14: Global Adult Preventable Vaccines Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Adult Preventable Vaccines Market Volume (K) By Region

Table 31: Global Adult Preventable Vaccines Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Adult Preventable Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Adult Preventable Vaccines Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Adult Preventable Vaccines Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Pfizer Inc. Basic Information And Sales Area

Table 52: Pfizer Inc.. Products Portfolio

Table 53: Merck & Co., Inc. Basic Information And Sales Area

Table 54: Merck & Co., Inc.. Products Portfolio

Table 55: GlaxoSmithKline plc (GSK) Basic Information And Sales Area

Table 56: GlaxoSmithKline plc (GSK). Products Portfolio

Table 57: Sanofi Pasteur Basic Information And Sales Area

Table 58: Sanofi Pasteur. Products Portfolio

Table 59: Moderna, Inc. Basic Information And Sales Area

Table 60: Moderna, Inc.. Products Portfolio

Table 61: Serum Institute of India Pvt. Basic Information And Sales Area

Table 62: Serum Institute of India Pvt.. Products Portfolio

Table 63: Bharat Biotech International Basic Information And Sales Area

Table 64: Bharat Biotech International. Products Portfolio

Table 65: CSL Limited (Seqirus) Basic Information And Sales Area

Table 66: CSL Limited (Seqirus). Products Portfolio

Table 67: Emergent BioSolutions Inc. Basic Information And Sales Area

Table 68: Emergent BioSolutions Inc.. Products Portfolio

Table 69: Daiichi Sankyo Company Basic Information And Sales Area

Table 70: Daiichi Sankyo Company. Products Portfolio

Table 71: Novavax, Inc. Basic Information And Sales Area

Table 72: Novavax, Inc.. Products Portfolio

Table 73: Sinovac Biotech Basic Information And Sales Area

Table 74: Sinovac Biotech. Products Portfolio

Table 75: Sinopharm Group Co. Basic Information And Sales Area

Table 76: Sinopharm Group Co.. Products Portfolio

Table 77: Johnson & Johnson (Janssen) Basic Information And Sales Area

Table 78: Johnson & Johnson (Janssen). Products Portfolio

Table 79: AstraZeneca plc Basic Information And Sales Area

Table 80: AstraZeneca plc. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Market Volume (K) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Volume (K) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Adult Preventable Vaccines Market Value (USD Million) By Region

Table 90: Global Adult Preventable Vaccines Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Application

Table 93: North America Market Value (USD Million) (2025-2032) By Types

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Application

Table 96: Europe Market Value (USD Million) (2025-2032) By Types

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Application

Table 102: South America Market Value (USD Million) (2025-2032) By Types

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 106: Global Adult Preventable Vaccines Market Volume (K) By Region

Table 107: Global Adult Preventable Vaccines Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Application

Table 110: North America Market Volume (K) (2025-2032) By Types

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Application

Table 113: Europe Market Volume (K) (2025-2032) By Types

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Application

Table 119: South America Market Volume (K) (2025-2032) By Types

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Adult Preventable Vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	21.64 billion
Revenue forecast in 2033	37.74 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Merck & Co., Inc.; GlaxoSmithKline plc (GSK); Sanofi Pasteur; Moderna, Inc.; Serum Institute of India Pvt.; Bharat Biotech International; CSL Limited (Seqirus); Emergent BioSolutions Inc.; Daiichi Sankyo Company; Novavax, Inc.; Sinovac Biotech; Sinopharm Group Co.; Johnson & Johnson (Janssen); AstraZeneca plc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options